Germany-based biosimilar manufacturer STADA Arzneimittel reports strong financial performance in 2023 with double digit sales growth and billions in profits. The CEO credits the company’s success on their strong company culture and focus for innovation.
STADA Annual Report 2022 vs 2023
In 2023, STADA Arzneimittel’s group adjusted sales were up by 14% with a 19% improvement rate in earnings before interest, taxes, depreciation, and amortization (EBITDA), according to the company’s annual earnings report. Overall, 2023 sales were around $4 billion and $870 million in the annual EBITDA. Additionally, the company had a total of 95 business development and licensing deals signed in 2023.
This past November, about 91% of STADA colleagues voluntarily participated in a global employee survey on various industry benchmarks, which exceeded expectations. Around 88% of the survey participating employees expressed confidence towards the company’s successful business objectives.
Peter Goldschmidt, CEO of STADA, claimed, “Our performance continues to progress ahead of major competitors. Our culture with entrepreneurial focus is delivering new launches from our extensive pipelines, on top of strong organic growth.”
Specialty was STADA’s fastest growing product segment in 2023 and hit a company milestone as it entered the European ophthalmology market. A 25% increase in sales was achieved, leading to a total of around $8 million dollars. STADA’s sixth marketed ranibizumab biosimilar (Ximluci), is an alternative to the reference brand Lucentis (ranibizumab). Previous launches of similar biologics include Hukyndra (adalimumab biosimilar), Oyvas (bevacizumab biosimilar), and Movymia (teriparatide).
The Consumer Healthcare product segment by STADA largely drove the sales growth up in 2023, accounting for 40% of the total Group sales. Goldschmidt’s claims were supported by the company’s outperformance against other top competitors as their sales advanced up to $1.6 billion, a 17% increase.
This success has awarded STADA Europe’s fourth largest Consumer Healthcare supplier in sales. Grippostad, Silomat, Multilind, Elotrans, and Hoggar were among some of the brands that had the ability to grow significantly, establishing market leadership in Germany. In conjunction with Germany, Belgium, France, Italy, and Spain had improvements in Consumer Healthcare market positions too.
In July 2023, STADA acquired the brands known as Antistax (red-vine-leaf-extract), Lomudal (chromoglycate sodium), Omnivit (carbonyl iron, folic acid, zinc sulfate, vitamin B complex, vitamin C), and Opticrom (cromolyn sodium ophthalmic solution) from Sanofi. This status elevated STADA’s partnership appeal as they continue to build upon their existing commercialization throughout 20 European countries.
Generics were a major contributor to the 6% increase in sales, with STADA earning $1.6 billion. Launches assisting in this progress include anticoagulant apixaban, the diabetes drug sitagliptin, analgesic tapentadol, and medications that reverse the effect of muscle relaxants known as tacrolimus for transplantation and sugammadex.
Annual sales for Stelara are around $2.7 billion in Europe but STADA’s ustekinumab biosimilar, Uzpruvo, introduced competition after it received positive attributes for the first time by the European Medicines Agency. By the end of 2023, an increasing number of patients in Germany began Kinpeygo (budesonide), the first treatment approved in Europe for rare kidney diseases.
An improved independent assessment of the Group’s environmental, social, and governance (ESG) risk was reflected in December 2023. STADA was ranked as the top 6% of global pharmaceutical companies when considering ESG. An assessment compared STADA with 900 other global pharmaceutical companies and expressed their dedication to working as a trusted partner with society, customers, regulators, and capital market stakeholders to ensure success.
Goldschmidt concluded the expense report, “With our unique culture driving performance, I am confident that we have the team, the products, and the pipeline in place to maintain our strong growth momentum.”
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Biosimilars Offer New Hope for European Patients Facing High Eculizumab Costs
May 20th 2025Eculizumab biosimilars could provide European patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome better access to care for a better price, similar to successes seen in other biosimilar markets, according to a review.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.